A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors

Gender Preference	None
Age Group	0 - 99 years
Research Start Date	February 22, 2013
Research End Date	August 22, 2023
Principal Investigator	Richard Ahrens, MD
Description	The purpose of this research study is to determine the number of patients affected by Fibrosing Colonapathy in people with cystic fibrosis and to learn more about what might cause it, including use of pancreatic enzyme supplements.
Contact Info	Mary Teresi, PharmD mary-teresi@uiowa.edu
Keywords	span itemProp='description'>Cystic Fibrosis ; Fibrosing Colonapathy ;

Contact